PD-L1 IHC 28-8 pharmDx Interpretation Manual -US Version
Intended Use in Squamous Cell Carcinoma of the Head and Neck FDA-approved for in vitro diagnostic use.
PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC) and melanoma tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity. Tumor PD-L1 status is defined by indication specific staining interpretation.
How to Use the PD-L1 IHC 28-8 pharmDx Interpretation Manual
This PD-L1 IHC 28-8 pharmDx Interpretation Manual is provided as a tool to help guide pathologists and laboratory technicians to achieve correct and reproducible results. The goal of this manual is to familiarize you with the requirements for scoring SCCHN specimens stained with PD-L1 IHC 28-8 pharmDx. Photomicrographs of example cases are provided for reference.
PD-L1 IHC 28-8 pharmDx instructions for use (IFU) contain guidelines and technical tips for ensuring high-quality staining in your laboratory.
Review of this PD-L1 IHC 28-8 pharmDx Interpretation Manual will provide a solid foundation for evaluating SCCHN specimens stained with PD-L1 IHC 28-8 pharmDx. For more details, please refer to the current version of PD-L1 IHC 28-8 pharmDx IFU provided or visit www.agilent.com.
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Limiting damage to healthy tissue
Inactivation of T cells limits damage to healthy tissue.
The tumor escapes detection
Inactivation of T cells reduces tumor cell killing.
Immuno-oncology therapies harness the immune response to fight tumors
Blocking PD-L1 enables cytotoxic T cells to actively remove tumor cells.
Clinical utility of PD-L1 IHC 28-8 pharmDx was evaluated in CHECKMATE-141, an open label, randomized Phase 3 clinical trial of nivolumab vs. therapy of investigator's choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).
(1)
The Phase 3 CHECKMATE-141 trial demonstrated a statistically significant improvement in OS for subjects randomized to nivolumab as compared with investigator's choice at a pre-specified interim analysis (78% of the planned number of events for final analysis).
A pre-specified exploratory sub-group analysis using PD-L1 IHC 28-8 pharmDx was performed. Results from the analysis are below.
The median OS was 7.5 months for nivolumab subjects compared to 5.1 months for investigator's choice subjects with a hazard ratio of 0.70 (95% CI: 0.53, 0.92).
Detection of PD-L1 expressing tumor cells in squamous cell carcinoma of head and neck (SCCHN) patient specimens may indicate an enhanced survival benefit to OPDIVO (nivolumab) treatment for the patient.
( 
Primary Study Objective:
To compare OS of nivolumab to investigator's choice in patients with metastatic or recurrent SCCHN who had experienced disease progression during or within 6 months of receiving platinum-based therapy administered in either the adjuvant, neo-adjuvant, primary (unresectable locally advanced) or metastatic setting.
Secondary Study Objectives:
To compare Progression Free Survival (PFS) of nivolumab to investigator's choice.
To compare Objective Response Rate (ORR) of nivolumab to investigator's choice.
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(60/327) Frequencies of tumor PD-L1 expression at each of the predefined baseline expression levels in all randomized subjects in CHECKMATE-141 are presented in Table 2 . Optimal staining performance is achieved by adhering to the PD-L1 IHC 28-8 pharmDx protocol. The following are tips for optimizing staining performance. Technical problems related to the performance of PD-L1 IHC 28-8 pharmDx may arise; those involving specimen collection, specimen preparation prior to performing the test and problems involving the actual performance of the test itself. Technical problems of the test can be minimized with a thorough understanding of the product instructions by the user.
Specimen Collection and Processing
Specimens must be handled in a way which preserves the tissue for immunohistochemical staining. Tissue should be stained and interpreted as close to time of biopsy as possible. Stability of PD-L1 immunoreactivity in tissue blocks has not been assessed. Tissue may be susceptible to loss of PD-L1 immunoreactivity with age. Confirm appropriate intact tumor morphology and the presence of sufficient tumor cells for evaluation. Use recommended methods of tissue processing for all specimens.
Control Tissue
Differences in processing and embedding in the user's laboratory may produce significant variability in results. Include positive and negative control tissue in each staining run, in addition to PD-L1 IHC 28-8 pharmDx Control Slides.
Select positive and negative control tissue from fresh SCCHN specimens. Fix, process, and embed the control tissue in the same manner as patient specimens. Control tissue processed differently from the patient specimen validates reagent performance only and does not verify tissue preparation. The ideal positive control tissue shows weak to moderate PD-L1 expression. The variety of different cell types present in most tissue sections offers internal negative control sites; this should be verified by the user. A suggested SCCHN-negative control tissue is one that shows no staining in tumor cells but possesses stained immune cells such as macrophages and lymphocytes.
Tissue Processing
Formalin-fixed, paraffin-embedded tissues are suitable for use. Block specimens into a thickness of 3 mm or 4 mm, fix in 10% Neutral Buffered Formalin (NBF), and dehydrate and clear in a series of alcohols and xylene, followed by infiltration with melted paraffin. An ischemia time from excision to fixation start time of less than 30 minutes followed by immersion in 10% neutral buffered formalin for 24-48 hours is recommended. The paraffin temperature should not exceed 60 °C. The use of PD-L1 IHC 28-8 pharmDx on decalcified tissues has not been validated and is not recommended. Cut tissue specimens into sections of 4-5 μm. After sectioning, mount tissues on FLEX IHC microscope slides, Code K8020, or Fisherbrand Superfrost Plus charged slides and place in a 58 ± 2 °C oven for 1 hour. To preserve antigenicity, tissue sections, once mounted on slides, should be stored in the dark at 2-8 °C, or room temperature up to 25 °C, and stained within 4 months of sectioning. Slide storage and handling conditions should not exceed 25 °C at any point post-mounting to ensure tissue integrity and antigenicity.
PD-L1 IHC 28-8 pharmDx Staining Procedure PD-L1 IHC 28-8 pharmDx reagents and instructions have been designed for optimal performance. Further dilution of the reagents, alteration of incubation times, temperatures, or materials may give erroneous results.
Reagent Storage
Store all components of PD-L1 IHC 28-8 pharmDx, including Control Slides, in the dark at 2-8 °C when not in use on Autostainer Link 48.
Reagent Preparation
Equilibrate all components to room temperature (20-25 °C) prior to immunostaining. Do not use after the expiration date printed on the outside package.
EnVision FLEX Target Retrieval Solution, Low pH
Dilute EnVision FLEX Target Retrieval Solution, Low pH (50x) 1:50 using distilled or deionized water (reagent-quality water). One 30 mL bottle of concentrate provides 1.5 L of working solution which is sufficient to fill one PT Link Pretreatment Module tank and will treat up to 24 slides per use. The pH of the working solution should be 6.1 ± 0.2. Discard Low pH working solution after three uses. Do not use after 5 days following dilution.
EnVision FLEX Wash Buffer, Code K8007 Dilute EnVision FLEX Wash Buffer (20x) 1:20 using distilled or deionized water (reagent-quality water). Store unused working solution at 2-8 °C for no more than one month. Wash buffer can also be stored for up to 7 days at 25 °C. Discard if cloudy in appearance. 
DAB+ Substrate-Chromogen Solution
Controls to Assess Staining Quality
Control slides are recommended to determine that PD-L1 IHC 28-8 pharmDx results (generated by the system containing reagents, instrument hardware and software) are valid and the reagents are functioning properly. For each staining run include the following control slides:
One PD-L1 IHC 28-8 pharmDx Control Slide stained with the Primary Antibody in each staining run.
Two positive control tissue slides (one stained with Primary Antibody and the other stained with Negative Control Reagent) for each set of test conditions. Two negative control tissue slides (one stained with Primary Antibody and the other stained with Negative Control Reagent).
Lastly, for each patient specimen stained with Primary Antibody, include a sequential section of patient specimen stained with Negative Control Reagent.
Staining Protocol
Program slides by selecting PD-L1 IHC 28-8 pharmDx staining protocol from the options in the DakoLink drop down menu. All of the required steps and incubation times for staining are preprogrammed in the DakoLink software. Print and attach slide labels to each slide.
Deparaffinization, Rehydration and Target Retrieval
Use PT Link Pretreatment Module to perform a deparaffinization, rehydration and target retrieval 3-in-1 procedure.
Set Preheat and Cool to 65 °C, and set Heat to 97 °C for 20 minutes.
Fill PT Link tanks with 1.5 L per tank of prepared EnVision FLEX Target Retrieval Solution, Low pH, working solution to cover the tissue sections.
Preheat the Target Retrieval Solution, Low pH to 65 °C.
Immerse Autostainer racks containing mounted, FFPE tissue sections into the pre-heated Target Retrieval Solution, Low pH in PT Link tank. Start the PT Link program and incubate for 20 minutes at 97 °C.
When target retrieval incubation has been completed and the temperature has cooled to 65 °C, remove each Autostainer slide rack with slides from the PT Link tank and immediately place the rack with slides into a tank (e.g., PT Link Rinse Station, Code PT109) containing room temperature EnVision FLEX Wash Buffer working solution.
Leave Autostainer rack with slides in room temperature EnVision FLEX Wash Buffer for 5 minutes.
Staining and Counterstaining
Place the Autostainer rack with slides on the Autostainer Link 48. Ensure slides remain wet with buffer while loading and prior to initiating the run. Dried tissue sections may display increased non-specific staining.
Start the Autostainer to run the PD-L1 IHC 28-8 pharmDx protocol. The instrument performs the staining and counterstaining procedures by applying the appropriate reagent, monitoring the incubation time and rinsing slides between reagents. Counterstain slides for 7 minutes using EnVision FLEX Hematoxylin. Do not allow slides to dry prior to mounting.
Mounting
Use non-aqueous permanent mounting media. To minimize fading, store slides in the dark at room temperature (20-25 °C).
Example of Adequate Dehydration Procedure
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The following flow of slide review is recommended when conducting interpretation of PD-L1 IHC 28-8 pharmDx.
Refer to detailed description on pages 18-19. 1 2 3A 4A 5 6
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Negative Control Tissue Slides
Examine the negative SCCHN control tissue slides (one stained with Primary Antibody and the other with Negative Control Reagent) to confirm that there is no unintended staining. Any background staining should be of ≤ 1+ staining intensity. If unwanted specific plasma membrane staining of malignant cells occurs in the negative control tissue, all results with the patient specimens should be considered invalid. Do not use control tissue as an aid in interpretation of patient results.
Patient Specimen Stained with Negative Control Reagent
The Negative Control Reagent indicates non-specific background staining and allows better interpretation of patient specimen stained with the Primary Antibody. Examine the patient specimen stained with Negative Control Reagent to identify non-specific background staining. Staining by the Negative Control Reagent must not show positive membrane staining and non-specific background should be ≤ 1+. If staining is not satisfactory, results with the patient specimen should be considered invalid.
Patient Specimen Stained with Primary Antibody
Staining should be assessed within the context of any non-specific background staining of the patient specimen stained with Negative Control Reagent. A minimum of 100 viable tumor cells should be present in the PD-L1 stained patient specimen slide to determine the percentage of stained cells.
Tips and Special Considerations
Include the entire specimen for evaluation of PD-L1 expression Use higher magnifications to confirm cell types and areas absent of staining Be careful not to overlook weak 1+ staining, which can be missed at 4x and 10x
Non-evaluable specimens: The specimen should be considered non-evaluable if there are fewer than 100 viable tumor cells. A different section from the same block or another block from the same patient may be required to present a sufficient quantity of viable tumor cells for PD-L1 IHC 28-8 pharmDx evaluation.
Indeterminate specimen: The tumor cell membrane has been hampered for reasons attributed to the biology of the tumor tissue sample rather than improper sample preparation. For example, high cytoplasmic staining of the tumor cells can hamper scoring of the membrane staining. An additional cut section or section from another block of the same patient may be required for PD-L1 IHC 28-8 pharmDx evaluation.
PD-L1 IHC 28-8 pharmDx evaluation must be performed by a pathologist using a bright field microscope. Before examining the patient specimen for PD-L1 staining, it is important to examine the hematoxylin and eosin (H&E) and controls first to assess staining quality. Examine a serial section of the patient specimen stained with H&E for histology and preservation quality. Then, examine PD-L1 IHC 28-8 pharmDx Control Slide, followed by the positive and negative control tissue slides, stained with Negative Control Reagent and Primary Antibody for each set of test conditions. Lastly, examine the patient specimen stained with Negative Control Reagent and Primary Antibody to assess the percentage staining of viable tumor cells.
PD-L1 staining is defined as complete circumferential and/or partial linear plasma membrane staining of tumor cells at any intensity. Only the PD-L1 IHC 28-8 pharmDx Control Slide is provided in the PD-L1 IHC 28-8 pharmDx kit. Positive control tissue slides and negative control tissue slides should be supplied by the laboratory. Laboratory provided positive and negative control tissue may be included on the same slide as the patient specimen.
Patient Specimen Stained with H&E
An H&E stained section is required for the evaluation of histology and preservation quality. PD-L1 IHC 28-8 pharmDx and the H&E staining should be performed on serial sections from the same paraffin block of the specimen.
Foci of dysplasia and carcinoma in situ are excluded from scoring. An accompanying H&E section allows for the proper assessment of invasive carcinoma, carcinoma in situ, and adjacent normal epithelium.
PD-L1 IHC 28-8 pharmDx Control Slide
Examine the PD-L1 IHC 28-8 pharmDx Control Slide to ascertain that reagents are functioning properly. Each slide contains sections of cell pellets with positive and negative PD-L1 expression, see 
Non-Specific Background Staining
Background staining is defined as diffuse, non-specific staining of a specimen. It is caused by several factors. These factors include, but are not limited to, pre-analytic fixation and processing of the specimen, incomplete removal of paraffin from sections, and incomplete rinsing of slides.
The use of fixatives other than 10% neutral buffered formalin may be a source of background staining. 
Immune Cells
Intense staining of inflammatory cell infiltrate in the tumor may occur. Inflammatory cells are not included in determining the percent positive staining of the tumor.
Necrosis
Necrotic tissue may show non-specific staining and should not be included in scoring percent positivity of the tumor.
Squamous Cell Differentiation
Due to cell differentiation in this tumor type, a wide range of cell sizes may be observed. Approximating percent positive staining by staining area may produce an inaccurate score due the wide range of cell sizes. See page 19 for instructions on scoring the patient specimen stained with primary antibody. 
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